News | January 12, 2022
Indian pharma industry registers 5.3% YoY revenue growth in Dec 2021 : Ind-Ra
Ind-Ra expects revenue growth of over 12% in 2022.
Ind-Ra expects revenue growth of over 12% in 2022.
In addition to its favourable activity profile, IBIO123 is formulated for administration by inhalation providing an efficient, rapid and non-invasive delivery method into the lungs via the respiratory tract
Recent Study by Columbia University finds Mylab’s CoviSelf can detect the Omicron variant successfully
Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
It has also been granted permission to conduct trials for booster dose
Doxycycline Hyclate Delayed Release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
The first pilot study from India analyzing Covaxin-Covishield mixed doses
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
Subscribe To Our Newsletter & Stay Updated
